PCVX

Vaxcyte, Inc.

A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.

CUSIP: 92243G108HealthcareUS2 holders

Ownership Activity Financials Filings

PCVX

PCVX

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Other Events

Other Events